<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475343</url>
  </required_header>
  <id_info>
    <org_study_id>No.018</org_study_id>
    <nct_id>NCT02475343</nct_id>
  </id_info>
  <brief_title>A Novel Method to Assess the Cornea Biomechanical Properties With Schiotz Tonometer</brief_title>
  <official_title>A Novel Method to Assess the Cornea Biomechanical Properties With Schiotz</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhiwei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to use Schiotz tonometer to evaluate the corneal biomechanical properties.
      The administration of Schiotz tonometer is according to the routine protocol which is use to
      measure intra-ocular pressure. The results obtained from Schiotz tonometer will be compared
      with results obtained from ORA and/or Corvis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schiotz tonometer, since it firstly be developed more than 100 years ago by Hjalmar Schiotz,
      has been regarded as a classical method to evaluate intraocular pressure (IOP). In present
      study, we aims to measure the corneal biomechanical properties with schiotz tonometer and
      elucidate the clinical significance of this novel measurement. The corneal biomechanical
      property was calculated with subtracting the value displayed under loaded weight 5.5g from
      that under loaded weight 7.5g. We named the corneal biomechanical properties obtained with
      schiotz tonometer as Mulee factor, and the formulation is Mulee factor=value under loaded
      weight 7.5g (Value 7.5G)-value under loaded weight 5.5g (Value 5.5G).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Mulee factor obtained with Schiotz tonometer as a measure of cornea biomechanical property</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Mulee factor= Value displayed with Schiotz tonometer under 7.5g load-Value displayed with Schiotz tonometer under 5.5g load</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People without keratoconus, history of ocular surgery, and other diseases mentioned in exclusion criteria. Normal people will receive treatment or measurement including: Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking, Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Keratoconic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with keratoconus.Keratoconic patients will receive treatment or measurement including:Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking,Ocular morphology measurement,and routine ophthalmic examination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients received keratoplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received keratoplasty. Patients received keratoplasty will receive treatment or measurement including:Schiotz tonometer measurement,Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination..</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Schiotz tonometer</intervention_name>
    <description>The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Keratoconic patients</arm_group_label>
    <arm_group_label>Patients received keratoplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UVA/riboflavin</intervention_name>
    <description>The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Keratoconic patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>femto-LASIK</intervention_name>
    <description>The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Patients received keratoplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tomey SP-100 Pchymeter , Topolyzer Vario</intervention_name>
    <description>Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Keratoconic patients</arm_group_label>
    <arm_group_label>Patients received keratoplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Topcon CT-80, Topcon, Japan</intervention_name>
    <description>Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Keratoconic patients</arm_group_label>
    <arm_group_label>Patients received keratoplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Corvis-ST</intervention_name>
    <description>Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Keratoconic patients</arm_group_label>
    <arm_group_label>Patients received keratoplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  People without the disease mentioned in exclusion criteria part.

        Exclusion Criteria:

          -  Patients with ocular diseases including keratitis, conjunctivitis, history of chronic
             eye/systemic diseases except myopia and keratoconus, history of ocular surgery except
             LASIK, pregnant or lactating females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoying Mu, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiwei Li, MD.</last_name>
    <phone>+86-18053106729</phone>
    <email>zhiweiovs@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihua Wang, MD</last_name>
      <email>wang_glasses@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Zhiwei Li</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

